A landmark analysis confirmed that clinical benefits emerged beyond the initial 30-day procedural window, reinforcing the hypothesis that SGLT2 inhibitors may facilitate reverse remodeling and durable myocardial protection in patients with severe AS following TAVI [120]. The gene discussed is SLC5A2; the disease is aortic stenosis.